Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 271 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Refractory Depression Clear all
Completed Not applicable Interventional Results available

Wake Therapy in the Treatment of Depression

NCT01431573
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
Wake Therapy, light box, Lithium
Behavioral · Device · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

Nicotinic Receptor Augmentation of SSRI Antidepressants

NCT00319319
View directory record Official record
Conditions
Depressive Disorder
Interventions
Mecamylamine hydrochloride (Inversine)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 19, 2007 · Synced Oct 29, 2026, 8:21 PM EDT
Completed No phase listed Observational

Deciphering Principles of Network Dynamics Underlying Depression Symptom Severity From Multi-day Intracranial Recordings in Patients With Major Depression

NCT06953362
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Direct Neural Electrical Stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Months to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 1 Interventional

Home-administered tDCS for Treatment of Depression

NCT04781127
View directory record Official record
Conditions
Unipolar Depression, Treatment Resistant Depression
Interventions
Soterix Medical mini-CT tDCS stimulator
Device
Lead sponsor
Soterix Medical
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 29, 2026, 8:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing

NCT05418894
View directory record Official record
Conditions
Treatment Resistant Depression, Epilepsy
Interventions
Device: Directional Deep Brain Stimulation
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
22 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

NCT03051256
View directory record Official record
Conditions
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions
REL-1017, Placebo
Drug
Lead sponsor
Relmada Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Little Rock, Arkansas • Garden Grove, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 29, 2026, 8:21 PM EDT
Recruiting Not applicable Interventional

Brain Stimulation for Severe Depression

NCT05393622
View directory record Official record
Conditions
Depression Severe
Interventions
INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION
Device
Lead sponsor
Inner Cosmos Inc
Industry
Eligibility
21 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Not applicable Interventional Results available

Low Frequency TMS for Depression in Epilepsy

NCT03105700
View directory record Official record
Conditions
Epilepsy, Depressions, Refractory
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 4 Interventional

Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression

NCT02141776
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial direct current stimulation (t-DCS), Sham Controlled Arm
Device · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 1 Interventional

Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)

NCT02911597
View directory record Official record
Conditions
Depression
Interventions
Naltrexone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression

NCT00837486
View directory record Official record
Conditions
Depression
Interventions
Reclaim™ DBS System
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Charlestown, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958
View directory record Official record
Conditions
Treatment Resistant Depressive Disorder
Interventions
Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 64 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 29, 2026, 8:21 PM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

NCT06303739
View directory record Official record
Conditions
Refractory Depression, Treatment Resistant Depression
Interventions
psilocybin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)

NCT01898429
View directory record Official record
Conditions
Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant, Depression, Bipolar
Interventions
SCC DBS
Device
Lead sponsor
Paul Holtzheimer
Other
Eligibility
22 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Not applicable Interventional

Neurofeedback for Treatment Resistant Depression

NCT03428828
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Amygdala Neurofeedback, Parietal Neurofeedback
Device
Lead sponsor
Kymberly Young
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients

NCT02935595
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 29, 2026, 8:21 PM EDT
Not listed Phase 2 Interventional

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

NCT04433845
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 4 Interventional Results available

Abilify as an Adjunctive Treatment for Refractory Depression

NCT00220636
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Aripiprazole
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Early Phase 1 Interventional

Feasibility, Safety and Efficacy of Deep Brain Stimulation for Depression

NCT00555698
View directory record Official record
Conditions
Depression
Interventions
Deep Brain Stimulations for Depression
Device
Lead sponsor
Ali Rezai, MD
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

NCT02360280
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
ketamine, midazolam
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

NCT00163059
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
NMDA Antagonist, CP-101,606 (traxoprodil)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2006 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 4 Interventional Results available

12- Week Open Label Treatment of Refractory Bipolar Depression

NCT00223496
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 29, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

NCT05113771
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Liafensine, Placebo
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
41
States / cities
Huntsville, Alabama • Phoenix, Arizona • Garden Grove, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 29, 2026, 8:21 PM EDT
Completed No phase listed Observational

Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)

NCT04519957
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Not listed
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Timeline
2020 – 2022
U.S. locations
4
States / cities
La Jolla, California • San Diego, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 29, 2026, 8:21 PM EDT